The autoimmune disease diagnostics market was valued at USD 4,253.30 million in 2021 and is projected to reach USD 6,298.98 million by 2027 registering a CAGR of nearly 6.8% during the forecast period.
The first wave of the COVID-19 pandemic has disrupted almost all areas of the health care services to some extent throughout the world. The negative impact of COVID-19 on patients with autoimmune diseases has also been recognized. According to an article titled "The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned" published in October 2021, a decrease in the number of autoantibody tests was observed in all European countries in the year 2020 compared to 2019.
All autoantibody tests saw a 13% decrease, ranging from 1.4% in Switzerland to 25.5% in the United States (Greece). The decrease was most pronounced in all countries during the first wave of the pandemic (March-May 2020), with an overall decrease of 45.2% in those three months. The decrease was less pronounced(6.8%) in the second wave of the pandemic (October-December 2020).
The rising autoimmune diseases is the major factor behind the market growth. According to scientists at the National Institutes of Health and their collaborators, autoimmunity, a condition in which the body’s immune system reacts with components of its own cells, appears to be increasing in the United States.
Also, as per the article published in January 2022, Autoimmune diseases are becoming more prevalent around the world. The global spread of Western diets is linked to higher levels of autoimmune disease. As per the same source, Tens of millions of people develop autoimmune diseases in the US alone, and the number of cases has been increasing in recent decades. Thus, the increasing number of autoimmune diseases is driving the market growth.
To Know More Please visit:Autoimmune Disease Diagnostics Market